Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

2 giugno 2026 aggiornato da: Yan Bi, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

A Multicenter Cross-Sectional Study Evaluating the Diagnostic Accuracy of the Liver Inflammation Index for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Patients With Concurrent Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Fatty Liver Disease

This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This study is a national, multicenter, real-world, cross-sectional observational trial designed to assess the clinical utility and diagnostic accuracy of the Liver Inflammation Index for identifying Metabolic Dysfunction-Associated Steatohepatitis (MASH) in patients with concurrent Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

The study plans to enroll a total of 10,000 participants across 22 major research centers in China. Data collection will be split into a prospective cohort (9,000 patients) and a retrospective cohort (1,000 patients). Each participating center will enroll between 100 and 2,000 subjects.

Study Procedures and Data Collection:

For all eligible participants, researchers will systematically collect comprehensive clinical data. This includes general demographic information, detailed past medical history, physical examination findings, and lifestyle questionnaires (assessing diet, physical activity, smoking, and alcohol consumption). Clinical assessments will involve standard laboratory tests to calculate the Liver Inflammation Index. Additionally, participants will undergo vibration-controlled transient elastography (using the iLivTouch device) to obtain the Ultrasound Attenuation Parameter (UAP) for steatosis grading and Liver Stiffness Measurement (LSM) for fibrosis staging.

Study Objectives:

The primary objective is to investigate the distribution and alterations of the Liver Inflammation Index in the Chinese T2DM and MAFLD population, and to evaluate the overall detection rate of MASH within this cohort.

Secondary objectives focus on stratifying the MASH detection rate based on several clinical variables:

The presence of comorbidities (including cardiovascular disease, chronic kidney disease, obesity, dyslipidemia, and hypertension).

The degree of hepatic steatosis (S1, S2, and S3), as determined by UAP results.

The severity of liver fibrosis (F0-F1, F2, F3, and F4), as determined by LSM results.

Demographic stratifications, including age, gender, and geographic region within China.

Identification of predictive risk factors associated with MASH in this specific patient population.

Exploratory Endpoints:

The study will explore the impact of modifiable, adverse lifestyle factors on the prevalence of MASH. Furthermore, a 5-year retrospective data collection (where hospital records permit) will be conducted to analyze the relationship between the MASH detection rate and various Liver-Related Events (LREs). LREs are defined as the occurrence of any of the following: Model for End-Stage Liver Disease (MELD) score ≥ 15, liver-related mortality, liver transplantation, progression to hepatocellular carcinoma, esophagogastric variceal bleeding, or hepatic decompensation (including ascites, overt hepatic encephalopathy, bacterial infections, and non-obstructive jaundice).

Tipo di studio

Osservativo

Iscrizione (Stimato)

10000

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Yan Bi, MD,PhD
  • Numero di telefono: 86-25-83-105302
  • Email: biyan@nju.edu

Backup dei contatti dello studio

  • Nome: Jin Li, MD,PhD
  • Numero di telefono: 86-25-83-105302
  • Email: jinli807@126.com

Luoghi di studio

  • Cina
    • Anhui
      • Bengbu, Anhui, Cina, 233004
        • Reclutamento
        • Department of Endocrinology, the First Affiliated Hospital of Bengbu Medical University
        • Contatto:
          • Xiaolei Hu
      • Hefei, Anhui, Cina, 230601
        • Reclutamento
        • Department of Endocrinology, the Second Affiliated Hospital of Anhui Medical University
        • Contatto:
          • Tianrong Pan
      • Wuhu, Anhui, Cina, 241000
        • Reclutamento
        • Department of Endocrinology, the Second Affiliated Hospital of Wannan Medical University
        • Contatto:
          • Junfei Gu
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510280
        • Reclutamento
        • Department of Endocrinology, Zhujiang Hospital, Southern Medical University
        • Contatto:
          • Jia Sun
      • Guangzhou, Guangdong, Cina, 511495
        • Reclutamento
        • Department of Obesity and Metabolic Diseases, Panyu Hospital of Traditional Chinese Medicine
        • Contatto:
          • Hui Li
      • Shenzhen, Guangdong, Cina, 518033
        • Reclutamento
        • Department of Endocrinology, the Eighth Affiliated Hospital, Sun Yat-sen University
        • Contatto:
          • Yunfeng Shen
    • Guangxi
      • Nanning, Guangxi, Cina, 530021
        • Reclutamento
        • Department of Endocrinology, the First Affiliated Hospital of Guangxi Medical University
        • Contatto:
          • Yingfen Qin
    • Guizhou
      • Zunyi, Guizhou, Cina, 563000
        • Reclutamento
        • Department of Endocrinology, the Affiliated Hospital of Zunyi Medical University
        • Contatto:
          • Xin Liao
    • Hainan
      • Haikou, Hainan, Cina, 570311
        • Reclutamento
        • Department of Endocrinology, Hainan General Hospital
        • Contatto:
          • Kaining Chen
    • Hennan
      • Zhengzhou, Hennan, Cina, 450099
        • Reclutamento
        • Department of Endocrinology, the First Affiliated Hospital of Henan University of CM
        • Contatto:
          • Suqin Shi
    • Hubei
      • Wuhan, Hubei, Cina, 430060
        • Reclutamento
        • Department of Endocrinology, Renmin Hospital of Wuhan University
        • Contatto:
          • Ling Gao
    • Hunan
      • Hengyang, Hunan, Cina, 421001
        • Reclutamento
        • Department of Endocrinology, the First Affiliated Hospital of University of South China
        • Contatto:
          • Xinhua Xiao
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210008
        • Reclutamento
        • Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
        • Contatto:
        • Investigatore principale:
          • Yan Bi, MD, PhD
        • Contatto:
        • Sub-investigatore:
          • Jin Li, MD, PhD
      • Suzhou, Jiangsu, Cina, 215006
        • Reclutamento
        • Department of Endocrinology, the First Affiliated Hospital of Soochow University
        • Contatto:
          • Bimin Shi, MD, PhD
          • Numero di telefono: 86-0512-65223637
          • Email: shibimin@163.com
      • Xuzhou, Jiangsu, Cina, 221009
        • Reclutamento
        • Department of Endocrinology, Xuzhou Central Hospital
        • Contatto:
          • Houfa Geng
    • Shandong
      • Qingdao, Shandong, Cina, 266000
        • Reclutamento
        • Department of Endocrinology, the Affiliated Hospital of Qingdao University
        • Contatto:
          • Yangang Wang
      • Weifang, Shandong, Cina, 261000
        • Reclutamento
        • Department of Metabolic Diseases and Weight Management, Weifang People's Hospital
        • Contatto:
          • Haixia Liu
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200000
        • Reclutamento
        • Department of Endocrinology, ZhongShan Hospital, Fudan University
        • Contatto:
    • Shanxi
      • Xi’an, Shanxi, Cina, 710032
        • Reclutamento
        • Department of Endocrinology and Metabolism, Xijing Hospital, Air Force Medical University
        • Contatto:
          • Xiangyang Liu
    • Yunnan
      • Kunming, Yunnan, Cina, 650011
        • Reclutamento
        • Department of Endocrinology, the Third People's Hospital of Yunnan Province
        • Contatto:
          • Li Gui
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310020
        • Reclutamento
        • Department of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
        • Contatto:
          • Jiaqiang Zhou
      • Wenzhou, Zhejiang, Cina, 325000
        • Reclutamento
        • Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University
        • Contatto:
          • Hong Zhu

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population consists of adult patients concurrently diagnosed with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Participants will be continuously enrolled from both outpatient clinics and inpatient departments across 22 major research centers and tertiary hospitals located in various geographic regions of China. This cohort represents a real-world clinical population seeking routine medical care, health evaluations, or regular follow-ups for their metabolic and endocrine conditions. Data will be collected through both prospective clinical assessments and retrospective medical record reviews.

Descrizione

Inclusion Criteria:

  1. Adults aged ≥18 years, with no restrictions on sex;
  2. Patients clinically diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the Chinese Society of Hepatology guideline Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Nonalcoholic) Fatty Liver Disease (2024 Edition), and additionally diagnosed with type 2 diabetes mellitus (T2DM) based on the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus (2024 Edition).

Exclusion Criteria:

  1. Presence of unhealed wounds, scars, or other conditions in the right upper abdominal region that are unsuitable for ultrasonographic examination;
  2. Development of other liver diseases during follow-up, including viral hepatitis, drug-induced liver injury, autoimmune liver disease, alcoholic liver disease, or other chronic liver diseases;
  3. History of hepatic decompensation;
  4. History of hepatectomy or liver transplantation;
  5. History of other malignancies;
  6. Presence of vascular liver disease, cystic fibrosis-associated liver disease, sarcoidosis, polycystic liver disease, congenital or rare hereditary liver diseases, mechanical cholestasis, secondary sclerosing cholangitis, or heart failure accompanied by hepatic venous congestion;
  7. History of transjugular intrahepatic portosystemic shunt (TIPS);
  8. Occurrence of acute hepatitis during follow-up (defined as alanine aminotransferase levels >5 times the upper limit of normal) or acute-on-chronic liver failure (ACLF);
  9. Clinical or subclinical hypothyroidism or hyperthyroidism.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
T2DM with MAFLD
Test diagnostico: iLivTouch (Vibration-controlled transient elastography)
A non-invasive diagnostic assessment performed using the iLivTouch device. This device simultaneously generates three key metrics: the Liver Inflammation Index (the primary target evaluated for its accuracy in detecting MASH), the Ultrasound Attenuation Parameter (UAP) for hepatic steatosis grading, and the Liver Stiffness Measurement (LSM) for fibrosis staging.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
To evaluate the overall detection rate of MASH in the Chinese T2DM and MAFLD population.
Lasso di tempo: Baseline
Baseline

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of Participants with MASH Stratified by Comorbidities
Lasso di tempo: Baseline
To evaluate and compare the detection rate of Metabolic Dysfunction-Associated Steatohepatitis (MASH) among subgroups of patients with specific concurrent conditions, including cardiovascular disease, chronic kidney disease, obesity, dyslipidemia, and hypertension.
Baseline
Proportion of Participants with MASH Stratified by Hepatic Steatosis Grades
Lasso di tempo: Baseline
To analyze the differences in the detection rate of MASH across varying degrees of hepatic steatosis (mild [S1], moderate [S2], and severe [S3]), as determined by the Ultrasound Attenuation Parameter (UAP) via transient elastography.
Baseline
Proportion of Participants with MASH Stratified by Liver Fibrosis Stages
Lasso di tempo: Baseline
To assess the differences in the detection rate of MASH among patients with different stages of liver fibrosis (F0-F1, F2, F3, and F4), as classified by Liver Stiffness Measurement (LSM) via transient elastography.
Baseline
Demographic Variations in MASH Detection Rate
Lasso di tempo: Baseline
To determine the detection rate of MASH stratified by key demographic factors, specifically gender and predefined age groups, to identify potential population-specific distribution patterns.
Baseline
Geographic Variations in MASH Detection Rate Across China
Lasso di tempo: Baseline
To evaluate the regional differences in the detection rate of MASH among the enrolled cohort of T2DM and MAFLD patients across different geographical regions within China.
Baseline
Identification of Risk Factors Associated with MASH
Lasso di tempo: Baseline
To identify and evaluate independent demographic, clinical, and laboratory predictors (risk factors) associated with the presence of MASH using multivariable logistic regression modeling.
Baseline

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Association Between Smoking and Alcohol Consumption Status and MASH Prevalence
Lasso di tempo: Baseline
Smoking status and alcohol consumption status will be collected at baseline and recorded as binary variables (Yes/No). The association between smoking status, alcohol consumption status, and the prevalence of MASH will be evaluated.
Baseline
Correlation Between MASH Detection and Retrospective Liver-Related Events (LREs)
Lasso di tempo: Baseline
To analyze the relationship between the current presence of MASH and a history of Liver-Related Events (LREs) by collecting retrospective patient data (where hospital records permit). LREs are defined as the occurrence of any of the following: Model for End-Stage Liver Disease (MELD) score ≥ 15, liver-related mortality, liver transplantation, progression to hepatocellular carcinoma, esophagogastric variceal bleeding, or hepatic decompensation (such as ascites, overt hepatic encephalopathy, or bacterial infections).
Baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaboratori

Fudan University
The Affiliated Hospital of Qingdao University
The First Affiliated Hospital of Soochow University
Xuzhou Central Hospital
Renmin Hospital of Wuhan University
The First Affiliated Hospital of University of South China
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Sir Run Run Shaw Hospital
Hainan General Hospital
First Affiliated Hospital of Wenzhou Medical University
Southern Medical University, China
The Second Hospital of Anhui Medical University
Zunyi Medical College
First Affiliated Hospital of Guangxi Medical University
Weifang People's Hospital
Eighth Affiliated Hospital, Sun Yat-sen University
Panyu Hospital of Traditional Chinese Medicine
The First Affiliated Hospital of Air Force Medicial University
The Third People's Hospital of Yunnan Province
The First Affiliated Hospital of Bengbu Medical University
Second Affiliated Hospital of Wannan Medical College

Investigatori

  • Investigatore principale: Yan Bi, MD,PhD, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 maggio 2026

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2027

Date di iscrizione allo studio

Primo inviato

23 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

2 giugno 2026

Primo Inserito (Effettivo)

8 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 2026-0142-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified participant data may be timely shared with qualified researchers upon request, subject to review and approval.

Periodo di condivisione IPD

Data will become available after study completion and primary publication for 3 years.

Criteri di accesso alla condivisione IPD

Data requests require a valid research proposal and signed data use agreement. Approval is contingent on compliance with applicable laws and ethical guidelines.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Diabete mellito di tipo 2 (T2DM)

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Azerbaijan

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi